论文部分内容阅读
目的研讨乳腺癌脑转移患者接受卡培他滨与放疗联合治疗的临床价值。方法从我院2014年8月-2015年8月选取50例乳腺癌脑转移病例做随机非盲法分组试验,Ⅰ组25例单纯接受放疗处理,Ⅱ组25例合用卡培他滨与放疗治疗,对该两种方案的临床应用情况做对比和评估。结果Ⅱ组患者接受治疗后的局部控制率(CR+PR)为80.0%,与Ⅰ组的56.0%相比显著提高,统计学成立(P<0.05)。Ⅱ组的毒副反应发生率、1年存活率各为36.0%和60.0%,与Ⅰ组的44.0%和52.0%相比差异不大,统计学不成立(P>0.05)。结论合用卡培他滨与放疗对乳腺癌脑转移患者进行治疗,可取得更理想的疗效,且毒副反应较轻,不影响1年存活率,值得推荐。
Objective To investigate the clinical value of capecitabine combined with radiotherapy in breast cancer patients with brain metastasis. Methods Fifty cases of brain metastases of breast cancer from August 2014 to August 2015 in our hospital were randomly divided into two groups: 25 cases in group Ⅰ received radiotherapy alone, 25 cases in group Ⅱ received capecitabine and radiotherapy , Compare and evaluate the clinical application of the two programs. Results The local control rate (CR + PR) of patients in group Ⅱ after treatment was 80.0%, which was significantly higher than 56.0% in group Ⅰ (P <0.05). The incidence of side effects and the 1-year survival rates of group Ⅱ were 36.0% and 60.0% respectively, which were not significantly different from 44.0% and 52.0% of group Ⅰ (P> 0.05). Conclusions The combination of capecitabine and radiotherapy for breast cancer patients with brain metastases, can achieve more satisfactory curative effect, and less toxic side effects, does not affect the 1-year survival rate, it is recommended.